Should you buy Revolution Medicines stock now?
Yes, the technical signal for Revolution Medicines is currently BUY. Revolution Medicines trades at $198.22 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 4.422 with falling momentum (signal: 4.485); RSI is at 62.2 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $207.00 points to 4.4% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Revolution Medicines stock?
The average analyst price target for Revolution Medicines is $207.00. The current price is $198.22, which gives an upside of 4.4%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $186.30 and $227.70.
Is Revolution Medicines a dividend stock?
No, Revolution Medicines does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Revolution Medicines stock?
Revolution Medicines is rated as a stock with high risk. the annual standard deviation is 67.8%, which classifies the stock as high risk.
Is Revolution Medicines overvalued?
Revolution Medicines is considered fairly valued – the price is close to the analyst price target. Revolution Medicines has the following valuation ratios: a P/S ratio of 9,035.1, a P/B ratio of 26.6. The stock trades close to the analyst price target and is considered fairly valued.
Is Revolution Medicines overbought?
No, Revolution Medicines is not overbought. RSI is at 62.2 (neutral zone). The technical indicators show: RSI is at 62.2 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 6.4% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Revolution Medicines earnings report?
The date of the next earnings report for Revolution Medicines has not been published yet. Check the company's investor calendar for updates.
Is Revolution Medicines shorted?
Yes, Revolution Medicines is shorted with 7.0% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Revolution Medicines stock?
No, insiders are not buying Revolution Medicines shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 11 sales. On a net basis, 10,903,120 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 37,609,685 $ sold. Active sellers include Patel Sushil, Anders Jack, Horn Margaret A and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Revolution Medicines a good stock?
Based on our total score, Revolution Medicines is rated as a poor stock with a total score of 36 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 2/100, Quality: 7/100, Momentum: 98/100. In addition: technical signal: Strong Buy. Whether Revolution Medicines is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Revolution Medicines stock?
The outlook for Revolution Medicines based on current data: the average analyst price target is $207.00 (+4.4%); the stock is in an uptrend (above SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Revolution Medicines stock rising?
Revolution Medicines is rising right now. The technical indicators show: the price is 6.4% above the 20-day average; short interest is 7.0% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Revolution Medicines go?
The average analyst price target for Revolution Medicines is $207.00, which corresponds to a potential gain of 4.4% from the current price of $198.22. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Revolution Medicines fall?
We lack enough history to give a specific floor for Revolution Medicines. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Revolution Medicines do?
Revolution Medicines er et klinisk biotekselskab, der fokuserer på præcisionsonkologi. De udvikler nye, målrettede behandlinger mod kræftformer, der er drevet af RAS-proteinet.
Revolution Medicines laver især RAS(ON)-hæmmere, som blokerer de muterede RAS-varianter. Deres pipe... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Revolution Medicines as an investment.
Did Revolution Medicines raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Revolution Medicines. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Revolution Medicines making money or losing money?
We have no current profitability data for Revolution Medicines. See the latest report in the earnings history above.
Can Revolution Medicines go bankrupt?
The bankruptcy risk of Revolution Medicines is rated as elevated. Altman Z2 (a model for assessing financial distress) is -1.82 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 13% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Revolution Medicines have a lot of debt?
No, Revolution Medicines has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 13%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
